# US 2013/0296570 A1 · Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0296570 A1
- Document ID: US20130296570A1
- Status: Published application
- Kind: A1
- Application number: 13/911,380
- Filed: 2013-06-06
- Published: 2013-11-07
- Earliest claimed: 2010-11-29
- Assignees: Progenics Pharmaceuticals, Inc.
- Applicants: Progenics Pharmaceuticals., Inc.
- Inventors: Alfred A. Avey; Julio Perez
- Web page: https://patentgrep.com/patent/US20130296570A1

## CPC

- C07D 489/08: Oxygen atom
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/02: without antiinflammatory effect
- G01N 30/24: Automatic injection systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

This invention relates to synthesis of (R),(R)-2,2′-bis-MNTX, as shown in Formula (I), and related methods and products.

## Claims

### Claim 1

A compound of Formula (I),
wherein X or Y is a counterion.

### Claim 2 (depends on 1)

The compound of claim 1, wherein each X independently can be the same or different counterion or each X can be covalently attached to the other X.

### Claim 3 (depends on 1)

The compound of claim 1, wherein X or Y is halide, sulfate, phosphate, sulfonate, nitrate, carboxylate, or an organic species.

### Claim 4 (depends on 1)

The compound of claim 1, wherein X is bromide.

### Claim 5 (depends on 1)

The compound of claim 1, wherein the compound is isolated with at least 0.5% purity.

### Claim 6 (depends on 1)

The compound of claim 1, wherein the compound is isolated with at least 1% purity.

### Claim 7 (depends on 1)

The compound of claim 1, wherein the compound is isolated with at least 5% purity.

### Claim 8 (depends on 1)

The compound of claim 1, wherein the compound is isolated with at least 10% purity.

### Claim 9 (depends on 1)

The compound of claim 1, wherein the compound is isolated with at least 15% purity.

### Claim 10 (depends on 1)

The compound of claim 1, wherein the compound is isolated with at least 25% purity.

### Claim 11 (depends on 1)

The compound of claim 1, wherein the compound is isolated with at least 50% purity.

### Claim 12 (depends on 1)

The compound of claim 1, wherein the compound is isolated with at least 75% purity.

### Claim 13 (depends on 1)

The compound of claim 1, wherein the compound is isolated with at least 95% purity.

### Claim 14 (depends on 1)

The compound of claim 1, wherein the compound is isolated with at least 97% purity.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The compound of claims 1-14, wherein the compound is a solid.

### Claim 16 (depends on 1)

The compound of claim 1, wherein the compound is packaged as a solution in a sealed bottle.

### Claim 17 (depends on 1)

The compound of claim 1, wherein the compound is packaged as a solution in a sealed bottle comprising a septum.

### Claim 18

A kit, comprising:
a compound of Formula (I),
wherein X or Y is a counterion, and indicia in or on the kit indicating that the compound is present in the kit.

### Claim 19 (depends on 18)

The kit of claim 18, wherein each X independently can be the same or different counterion or each X can be covalently attached to the other X.

### Claim 20 (depends on 18)

The kit of claim 18, wherein X or Y is halide, sulfate, phosphate, sulfonate, nitrate, carboxylate, or an organic species.

### Claim 21 (depends on 18)

The kit of claim 18, wherein X is bromide.

### Claim 22 (depends on 18)

The kit of claim 18, wherein the indicia indicates the purity of the compound.

### Claim 23 (depends on 18)

The kit of claim 18, wherein the indicia indicates the chemical structure of the compound by providing a chemical formula or a structural drawing.

### Claim 24

A method of synthesizing (R),(R)-2,2′-bis-MNTX, comprising:
reacting a first molecule of (R)-methylnaltrexone with a second molecule of (R)-methylnaltrexone in the presence of a catalyst and an oxidizing agent in amounts sufficient to form a compound of Formula (I),
wherein X or Y is a counterion.

### Claim 25 (depends on 24)

The method of claim 24, wherein each X independently can be the same or different counterion or each X can be covalently attached to the other X.

### Claim 26 (depends on 24)

The method of claim 24, wherein X or Y is halide, sulfate, phosphate, sulfonate, nitrate, carboxylate, or an organic species.

### Claim 27 (depends on 24)

The method of claim 24, wherein X is bromide.

### Claim 28 (depends on 24)

The method of claim 24, wherein the catalyst is present in 25 mol % or less relative to the amount of the first molecule of (R)-methylnaltrexone.

### Claim 29 (depends on 24)

The method of claim 24, wherein the catalyst is present in 10 mol % or less relative to the amount of the first molecule of (R)-methylnaltrexone.

### Claim 30 (depends on 24)

The method of claim 24, wherein the oxidizing agent is present in a stoichiometric amount relative to the amount of the (R)-first molecule of methylnaltrexone.

### Claim 31 (depends on 24)

The method of claim 24, wherein the catalyst is ferric bromide.

### Claim 32 (depends on 24)

The method of claim 24, wherein the oxidizing agent is hydrogen peroxide.

### Claim 33 (depends on 24)

The method of claim 24, further comprising isolating the compound as a solid.

### Claim 34 (depends on 33)

The method of claim 33, wherein the compound is isolated with at least 0.5% purity.

### Claim 35 (depends on 33)

The method of claim 33, wherein the compound is isolated with at least 1% purity.

### Claim 36 (depends on 33)

The method of claim 33, wherein the compound is isolated with at least 5% purity.

### Claim 37 (depends on 33)

The method of claim 33, wherein the compound is isolated with at least 10% purity.

### Claim 38 (depends on 33)

The method of claim 33, wherein the compound is isolated with at least 15% purity.

### Claim 39 (depends on 33)

The method of claim 33, wherein the compound is isolated with at least 25% purity.

### Claim 40 (depends on 33)

The method of claim 33, wherein the compound is isolated with at least 50% purity.

### Claim 41 (depends on 33)

The method of claim 33, wherein the compound is isolated with at least 75% purity.

### Claim 42 (depends on 33)

The method of claim 33, wherein the compound is isolated with at least 95% purity.

### Claim 43 (depends on 33)

The method of claim 33, wherein the compound is isolated with at least 97% purity.

### Claim 44

A method for determining an impurity, comprising:
injecting a reference solution comprising a compound of Formula (I),
wherein X or Y is a counterion, into an HPLC column under a set of conditions to obtain a first HPLC chromatogram, wherein the amount and/or chemical identity of the compound present in the reference solution is known;
injecting a sample solution comprising methylnaltrexone into the HPLC column under said set of conditions to obtain a second HPLC chromatogram; and
determining the presence and/or the amount of the compound in the sample solution.

### Claim 45 (depends on 44)

The method of claim 44, wherein each X independently can be the same or different counterion or each X can be covalently attached to the other X.

### Claim 46 (depends on 44)

The method of claim 44, wherein X or Y is halide, sulfate, phosphate, sulfonate, nitrate, carboxylate, or an organic species.

### Claim 47 (depends on 44)

The method of claim 44, wherein X is bromide.

### Claim 48 (depends on 44)

The method of claim 44, wherein the determining comprises comparing retention times of peaks in the first HPLC chromatogram and peaks in the second HPLC chromatogram to determine the presence of the compound in the sample solution.

### Claim 49 (depends on 44)

The method of claim 44, wherein the determining comprises quantifying peak areas of the sample solution and peak areas of the reference solution on the HPLC chromatograms and estimating from these the amount of the compound in the sample solution.

### Claim 50 (depends on 44)

The method of claim 44, wherein the sample solution comprises (R)-methylnaltrexone and/or (S)-methylnaltrexone.

### Claim 51 (depends on 44)

The method of claim 44, wherein the sample solution comprises a mixture of (R)-methylnaltrexone and (S)-methylnaltrexone.

### Claim 52 (depends on 44)

The method of claim 44, wherein the HPLC column is a reverse phase column and the column is eluted using a mobile phase comprising water, methanol, trifluoroacetic acid, or mixtures thereof.

### Claim 53 (depends on 44)

The method of claim 44, further comprising documenting in a written form the chemical identity of the compound and the amount of the compound as an impurity.

### Claim 54

A method for determining an impurity in a material consisting essentially of methylnaltrexone, comprising:
injecting into an HPLC column a sample solution containing the material and spiked with a reference compound having a known chemical structure of Formula (I),
wherein X is a counterion,
obtaining an HPLC chromatogram, and
determining the presence and/or the amount of the compound in the material.

### Claim 55 (depends on 54)

The method of claim 54, wherein each X independently can be the same or different counterion or each X can be covalently attached to the other X.

### Claim 56 (depends on 54)

The method of claim 54, wherein X or Y is halide, sulfate, phosphate, sulfonate, nitrate, carboxylate, or an organic species.

### Claim 57 (depends on 54)

The method of claim 54, wherein X is bromide.

### Claim 58 (depends on 54)

The method of claim 54, wherein the sample solution comprises (R)-methylnaltrexone.

### Claim 59 (depends on 54)

The method of claim 54, wherein the sample solution comprises a mixture of (R)-methylnaltrexone and (S)-methylnaltrexone.

### Claim 60 (depends on 54)

The method of claim 54, wherein the HPLC column is a reverse phase column and the column is eluted using a mobile phase comprising water, methanol, trifluoroacetic acid, or mixtures thereof.

### Claim 61 (depends on 54)

The method of claim 54, further comprising documenting in a written form the chemical identity of the compound and the amount of the compound as an impurity.

### Claim 62

A method for determining an impurity in a material consisting essentially of methylnaltrexone, comprising:
injecting a solution in which the material is dissolved into an HPLC column and obtaining an HPLC chromatogram;
determining the amount in the material of a compound known to have the structure of Formula (I),
wherein X or Y is a counterion, and
documenting in a written form the chemical identity of the compound and the amount of the compound as an impurity in the material.

### Claim 63 (depends on 62)

The method of claim 62, wherein the amount in the material of the compound is determined by (i) identifying a peak on the chromatogram that corresponds to a peak on a control chromatogram, (ii) identifying a peak on the chromatogram that corresponds to a relative retention time of a compound known to have the structure of Formula (I), and/or (iii) identifying a peak on the chromatogram that corresponds that corresponds to a known amount of a spike of the compound known to have the structure of Formula (I).

### Claim 64 (depends on 62)

The method of claim 62, wherein each X independently can be the same or different counterion or each X can be covalently attached to the other X.

### Claim 65 (depends on 62)

The method of claim 62, wherein X or Y is halide, sulfate, phosphate, sulfonate, nitrate, carboxylate, or an organic species.

### Claim 66 (depends on 62)

The method of claim 62, wherein X is bromide.

### Claim 67 (depends on 62)

The method of claim 62, wherein the sample solution comprises (R)-methylnaltrexone.

### Claim 68 (depends on 62)

The method of claim 62, wherein the sample solution comprises a mixture of (R)-methylnaltrexone and (S)-methylnaltrexone.

### Claim 69 (depends on 62)

The method of claim 62, wherein the HPLC column is a reverse phase column and the column is eluted using a mobile phase comprising water, methanol, trifluoroacetic acid, or mixtures thereof.
